Home    eJManager.com Add Your Journal   |    Follow on Twitter   |    Subscribe to List

Directory for Medical Articles
 

Open Access

Original Article

J App Pharm Sci. 2014; 4(12): 014-019


Combination of Cisplatin and Cinnamon Essential Oil Inhibits HeLa Cells Proliferation through Cell Cycle Arrest

Yonika Arum Larasati, Dyaningtyas Dewi Pamungkas Putri, Rohmad Yudi Utomo, Adam Hermawan, Edy Meiyanto.

Abstract
Cisplatin is drug of choice toward cervical cancer despite having many side effects, thus researches are conducted in order to find the effective and synergistic co-chemoterapeutic agent combined with cisplatin. In this study, we observed the potential of the cinnamon essential oil (CEO) isolated from Cinnamomum burmannii as co-chemoterapeutic agent of cisplatin on HeLa cells covering cytotoxic effect, cell cycle modulation and induction of apoptosis. Cytotoxic effect was determined by using MTT assay; while induction of apoptosis and cell cycle profile were observed by using flow cytometry. At 24 hours of incubation, CEO showed cytotoxic effect on HeLa cells with IC50 value of 250 ╬╝g/ml, while cisplatin showed cytotoxic effect with IC50 value of 18 ÁM. Combination of CEO and cisplatin reduced cells viability compared to cisplatin solely. Moreover, flow cytometry using annexin-V and PI showed that CEO and its combination with cisplatin induced apoptosis lower than cisplatin alone at 24 hours of incubation. Further analysis on the cell cycle progression showed that CEO induced S-phase arrest on HeLa cells, cisplatin induced G1 arrest, while combination of CEO and cisplatin induced G2/M arrest. Thus, the inhibition of HeLa cells growth at 24 hours is likely through cell cycle modulation rather than apoptosis.

Key words: cinnamon essential oil, cisplatin, HeLa cells, apoptosis, cell cycle


Full text links

Share this Article




ScopeMed Home
Follow ScopeMed on Twitter
Article Tools
Job Opportunities/Service Offers
eJManager OJMS
eJPort Journal Hosting
About ScopeMed
Terms & Conditions
Privacy Policy
Suggest a Journal
Publisher Login
Contact Us

The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Service of eJManager LLC Publishing for Scientific Publications. Copyright ę ScopeMed« Information Services.
Scopemed Buttons